Levi & Korsinsky Files Class Action for Sarepta Therapeutics Shareholders Amid Alleged Securities Fraud

In a significant move for investors, Levi & Korsinsky, LLP has officially notified Sarepta Therapeutics, Inc. shareholders about a class action securities lawsuit. This action arises against the backdrop of serious allegations regarding securities fraud that occurred between June 22, 2023, and June 24, 2025. Those who have invested in Sarepta Therapeutics, trading under the NASDAQ ticker SRPT, may find this news particularly pertinent, especially if they have experienced any losses during this time.

Class Action Details


The lawsuit aims to recover losses from those who were adversely impacted by the alleged fraudulent activities. According to the filed complaint, the defendants made misleading statements and concealed crucial information about ELEVIDYS, a prescription gene therapy designed for Duchenne muscular dystrophy patients. Concerns have been raised about the safety risks that ELEVIDYS poses to patients, leading to potentially severe implications for ongoing trials and future regulatory approvals.

The complaint specifically alleges that:
1. Safety Risks: The therapy posed significant safety risks that were not disclosed to investors.
2. Trial Protocol Failures: The trial protocols did not adequately identify severe side effects stemming from the treatment.
3. Regulatory Scrutiny: The adverse events associated with the treatment could cause the company to halt patient recruitment and dosing, leading to increased regulatory scrutiny.
4. Misleading Statements: As a result of these incidents, the defendants lacked a reasonable basis for their positive statements regarding the therapy, misguiding investors.

A Call to Action


Affected investors are urged to act quickly, as the deadline to request to be appointed as lead plaintiff is August 25, 2025. Being a lead plaintiff is not a prerequisite for participating in any recovery process; thus, interested investors are encouraged to contact Levi & Korsinsky’s team without delay to explore their options further. The firm has assured that there is no cost or obligation to get involved.

Why Choose Levi & Korsinsky?


Levi & Korsinsky boasts a robust track record in representing shareholders in complex securities litigation. Over the past two decades, the firm has recouped hundreds of millions of dollars for aggrieved investors, reinforcing its reputation within the financial and legal communities. With a dedicated team that has consistently ranked among the top securities litigation firms in the United States for seven consecutive years, they remain committed to providing high-stakes legal support tailored to investor needs.

For those interested in understanding their rights and potential recoveries, Levi & Korsinsky has made contact options available, including direct communication via email and phone. Investors can reach out to Joseph E. Levi, Esq. at [email protected] or by telephone at (212) 363-7500 for personalized assistance.

Final Thoughts


Sarepta Therapeutics, like many innovative biotech firms, occupies a volatile corner of the market. Investors are urged to stay informed about the developments of the lawsuit, as this could lead to significant ramifications for the company's future. As always, potential investors and current shareholders are encouraged to conduct thorough research and consult professionals in the field before making any investment decisions. Keep an eye on this evolving situation, as it may have lasting impacts on both the company and the market as a whole.

Topics Financial Services & Investing)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.